Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $93

Benzinga · 2d ago
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from $95 to $93.